<Anchor>



Recently, the Indian mutant virus is spreading rapidly in the United Kingdom and the United States, where vaccination rates are high. Research on mutated viruses with strong contagious power is being actively conducted, and it was found that the prevention effect was much higher when different types of vaccines were given during the first and second rounds of vaccination, or when another type of vaccine was added after vaccination was completed.



This is Cho Dong-chan, a medical reporter.



<Reporter>



Ko Jae-gyu, in his 40s, received the AstraZeneca vaccine in March.



But the second time on the 11th was the Pfizer vaccine.



It participated in an ongoing cross-inoculation clinical trial targeting 500 people in Korea.



[Jae-Gyu Ko/Participation in cross-inoculation clinical trial: (After cross-inoculation) After about three days, I was able to live my daily life very comfortably (I had a better life) than I thought.] In



previous cross-inoculation trials in other countries, safety was largely proven.



It also verifies the preventive effect, and mutation blocking ability has become important recently.



[Ahn Jinyoung/Professor of Infectious Diseases at Severance Hospital: Cross-vaccination with other effective vaccines against mutants will be necessary in the future. So (clinical) is being implemented in Korea too.]] As a



result of the British health authorities test, the effectiveness of preventing mutations in the UK was 93% for Pfizer, 66% for AstraZeneca, 88% for Pfizer and 60% for AstraZeneca in India.



However, AstraZeneca currently has the highest number of deaths when contracted with the Indian mutation at 92%.



It can be estimated that cross-inoculation with Pfizer and AstraZeneca can reduce both the infection rate and the fatality rate.



Vaccines made for mutations are also being developed.



Animal testing of AstraZeneca vaccine has been published as a paper.



If you get two doses of the existing vaccine, a certain amount of neutralizing antibodies that block mutations in South Africa and India are also produced.



However, since the previous vaccine was given one mutation at a time, there were 2-3 times more neutralizing antibodies mutated in South Africa and India than the two previous vaccines.



This time, I got the existing vaccine twice and got more mutations, so there were 7 to 8 times more.



However, there is an objection that two doses of the existing vaccine are not sufficient.



[Ahn Jin-young/Professor of Infectious Diseases at Severance Hospital: Some vaccine will need a booster (additional inoculation) when the antibody runs out. The evidence for this is not clearly established.] In



Korea, the first and second vaccines are inoculated, We are considering allowing cross-vaccination if additional vaccination is required.



(Video coverage: Kim Gyun-jong, video editing: Lee Seung-ryeol)

Keywords: